Article Text
Editorial
Dapagliflozin for type 1 diabetes: ensuring benefits outweigh the risks
Statistics from Altmetric.com
Footnotes
Competing interests None declared. Refer to the online supplementary files to view the ICMJE form(s).
Provenance and peer review Commissioned; externally peer reviewed.
Addendum On 12 February 2020, NICE approved ▼sotagliflozin for use with insulin for people with type 1 diabetes with BMI ≥27 kg/m2. The issues raised in this editorial also apply to the use of sotagliflozin.